Madrid

• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the … Recruiting
  2022-501677-39-00 5 2021-05-25 Adolescent Renal Allografts
• A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Recruiting
  2023-506145-38-00 3 2021-05-11 Treatment of participants with MF, MDS, ET, or MDS/MPN
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting
  2023-506838-68-00 9 2020-12-10 Renal cell carcinoma
• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl … Recruiting
  2022-501687-18-00 4 2020-10-28 Advanced malignancies and IAI diseases
• A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma. Recruiting
  2023-505261-84-00 5 2020-10-06 Primary high risk leiomyosarcoma or liposarcoma of retroperitoneal spa
• Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC Recruiting
  2023-503465-33-00 5 2020-07-03 Cholestasis
• A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting
  2023-510509-17-00 7 2020-06-17 Relapsed and/or refractory Acute Myeloid Leukemia
• A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generali … Recruiting
  2023-506688-32-00 5 2019-10-09 Primary Generalized Tonic-Clonic Seizures
• A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos … Recruiting
  2022-502784-37-00 4 2019-09-03 Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 ye
• Evaluation of the Pharmacokinetics and Safety of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis … Recruiting
  2023-505060-11-00 3 2019-06-19 Polyarticular Course Juvenile Idiopathic Arthritis
• Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib … Recruiting
  2024-512972-36-00 9 2019-05-23 Indolent B-Cell Non-Hodgkin Lymphoma
• CLINICAL TRIAL TO EVALUATE BLADDER INSTILLATION OF NEOADJUVANT CHEMOTHERAPY TO TRANSURETHRAL RESECTION OF THE BLADDER FOR THE PREVENTION OF … Recruiting
  2024-512683-53-00 6 2018-05-18 Non-muscle invasive bladder cancer
• A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Pri … Recruiting
  2023-508587-29-00 4 2018-04-03 Treatment of high-risk neuroblastoma patients with primary refractory
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 9 2017-01-13 pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting
  2024-512358-78-00 7 2015-01-20 Solid Tumors
• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe He … Recruiting
  2023-505805-18-00 5 2026-05-27 Hemophilia B
• A study to evaluate how well single and multiple doses of S072 are tolerated in healthy adult participants Recruiting
  2025-525039-15-01 1 2026-05-25 Pain
• A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitu … Recruiting
  2025-524857-15-00 1 2026-05-19 Advanced Solid Tumors
• A Phase 3 Trial of K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg Recruiting
  2025-523739-20-00 5 2026-05-14 Hypercholesterolemia
• Bioequivalence clinical trial of two formulations of canagliflozin Recruiting
  2026-525944-14-00 2 2026-05-14 Healthy volunteers
• A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting
  2025-523602-33-00 9 2026-05-13 Advanced or unresectable Hepatocellular Carcinoma (HCC)
• A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting
  2024-517337-41-00 5 2026-05-12 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

Showing 625–648 of 3,550 trials